1. Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials 
Stephen B Hanauer, Ulf Strömberg 
Clinical Gastroenterology and Hepatology 
Volume 2, Issue 5, Pages (May 2004)
DOI: /S (04)

2. Figure 1
Trial-specific (referred to as I, II, and III, respectively) and overall mean reductions of the CDAI, with 95% confidence intervals, obtained from the intent-to-treat endpoint analyses.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )

3. Figure 2
Trial-specific (referred to as I, II, and III, respectively) and overall mean reductions of the CDAI, with 95% confidence intervals, obtained from the protocol correct endpoint analyses.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )